Pioglitazone and Risk of Bladder Cancer in Patients With Type 2 Diabetes Mellitus.

Trial Profile

Pioglitazone and Risk of Bladder Cancer in Patients With Type 2 Diabetes Mellitus.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms PROBE-PIO
  • Most Recent Events

    • 04 Apr 2017 Planned End Date changed from 1 Jul 2016 to 1 Jul 2021.
    • 04 Apr 2017 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2020.
    • 01 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top